ASP Isotopes (NASDAQ:ASPI) Shares Gap Down After Insider Selling

Shares of ASP Isotopes Inc. (NASDAQ:ASPI) gapped down before the market opened on Monday following insider selling activity. The stock had previously closed at $5.37, but opened at $5.14. ASP Isotopes shares last traded at $5.3290, with a volume of 415,179 shares changing hands.

Specifically, Director Duncan Moore sold 11,642 shares of ASP Isotopes stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $5.21, for a total value of $60,654.82. Following the transaction, the director owned 1,044,928 shares of the company’s stock, valued at $5,444,074.88. The trade was a 1.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Heather Kiessling sold 23,124 shares of ASP Isotopes stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $5.48, for a total transaction of $126,719.52. Following the completion of the transaction, the chief financial officer directly owned 709,376 shares in the company, valued at approximately $3,887,380.48. This trade represents a 3.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In other news, COO Robert Ainscow sold 22,500 shares of ASP Isotopes stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $5.21, for a total value of $117,225.00. Following the transaction, the chief operating officer directly owned 1,490,317 shares of the company’s stock, valued at $7,764,551.57. This trade represents a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on ASPI shares. Canaccord Genuity Group reissued a “buy” rating and issued a $11.00 target price on shares of ASP Isotopes in a research report on Tuesday, April 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a research report on Friday, March 27th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $13.00.

ASP Isotopes Stock Performance

The company has a debt-to-equity ratio of 0.77, a current ratio of 12.23 and a quick ratio of 12.20. The firm has a market capitalization of $688.67 million, a price-to-earnings ratio of -2.56 and a beta of 3.59. The firm’s fifty day moving average is $5.05 and its 200 day moving average is $6.67.

ASP Isotopes (NASDAQ:ASPI) last posted its quarterly earnings results on Friday, April 10th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.70). The company had revenue of $33.32 million for the quarter, compared to analyst estimates of $2.03 million. ASP Isotopes had a negative return on equity of 161.55% and a negative net margin of 734.14%.

Institutional Trading of ASP Isotopes

A number of institutional investors have recently added to or reduced their stakes in ASPI. Alyeska Investment Group L.P. lifted its stake in ASP Isotopes by 73.4% in the fourth quarter. Alyeska Investment Group L.P. now owns 4,895,546 shares of the company’s stock valued at $26,191,000 after acquiring an additional 2,072,851 shares during the last quarter. UBS Group AG lifted its stake in ASP Isotopes by 150.3% in the fourth quarter. UBS Group AG now owns 2,406,457 shares of the company’s stock valued at $12,875,000 after acquiring an additional 1,445,165 shares during the last quarter. Marshall Wace LLP lifted its stake in ASP Isotopes by 3,669.1% in the third quarter. Marshall Wace LLP now owns 1,279,121 shares of the company’s stock valued at $12,305,000 after acquiring an additional 1,245,184 shares during the last quarter. Vanguard Group Inc. lifted its stake in ASP Isotopes by 37.9% in the third quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company’s stock valued at $43,451,000 after acquiring an additional 1,241,024 shares during the last quarter. Finally, Rovida Investment Management Ltd lifted its stake in ASP Isotopes by 45.5% in the third quarter. Rovida Investment Management Ltd now owns 3,200,000 shares of the company’s stock valued at $30,688,000 after acquiring an additional 1,000,000 shares during the last quarter. 16.80% of the stock is currently owned by institutional investors and hedge funds.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.